dasabuvir (Exviera) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Dasabuvir is a non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B palm polymerase inhibitor. It is used in the treatment of adult patients with chronic hepatitis C virus infection in combination with ombitasvir, paritaprevir, and ritonavir as the combination product Viekira Pak. Viekira PAK combines three direct-acting antiviral agents with distinct mechanisms of action and non-overlapping resistance profiles to target HCV at multiple steps in the viral lifecycle. Dasabuvir is extensively evaluated in large clinical trials and shown excellent sustained virological response among hepatitis C virus genotype1 patient population in combination with other oral direct acting antivirals, with good safety profile and tolerance.   NCATS

Chemistry

  • SMILES: COc1c(cc(cc1C(C)(C)C)N2C=CC(=O)NC2=O)c3ccc4cc(NS(=O)(=O)C)ccc4c3
  • InChIKey: NBRBXGKOEOGLOI-UHFFFAOYSA-N
  • Mol. Mass: 493.59
  • ALogP: 4.02
  • ChEMBL Molecules:
    dasabuvir  
    dasabuvir sodium  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Combination drugs

( ritonavir (Norvir), ombitasvir (Viekira Pak), paritaprevir (viekira pak), dasabuvir (Exviera) - other names: dasabuvir, ombitasvir, paritaprevir, and ritonavir, viekira xr )

Alternative names

abt-333 | dasabuvir | dasabuvir sodium | dasabuvir sodium monohydrate | exviera | n-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide | sodium 3-(3-tert-butyl-4-methoxy-5-{6­ [(methylsulfonyl)amino]naphthalene-2-yl}phenyl)-2,6-dioxo-3,6-dihydro-2h-pyrimidin-1-ide hydrate (1:1:1)

Organizations (24)

Research & Development (24)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (3)


 

Hepatitis C

Hepatitis C, Chronic

Infections

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Fasting (Phase 1)

Fibrosis (Phase 3)

Healthy Volunteers (Phase 1)

Hepacivirus (Phase 4)

Hepatitis B (Phase 2/Phase 3)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

Hepatitis Viruses (Phase 4)

HIV (Phase 3)

HIV Infections (Phase 2)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Liver Cirrhosis (Phase 3)

Renal Insufficiency, Chronic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 59
  • # of Trial Organizations: 24

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue